Log In
Print
BCIQ
Print
Print this Print this
 

recAP (recombinant alkaline phosphatase)

  Manage Alerts
Collapse Summary General Information
Company AM-Pharma B.V.
DescriptionIV recombinant human alkaline phosphatase
Molecular Target Lipopolysaccharide (LPS)
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase II
Standard IndicationRenal damage
Indication DetailsTreat acute kidney injury (AKI)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$600.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today